FCGRT and autoimmune hemolytic anemia: Another FcRn inhibitor, batoclimab (NCT04428255) is upon investigation in ITP and two others monoclonal antibodies targeting FcRn are being assessed in autoimmune hemolytic anemia (AIHA) and will probably be of interest in ITP: nipocalimab/M281 (NCT04119050), an aglycosylated IgG1, and SYNT001 (NCT03075878), a humanized IgG4 that binds to FcRn at both acid and neutral pH [70,75].